- Ayieko, James;
- Balzer, Laura B;
- Inviolata, Colette;
- Kakande, Elijah;
- Opel, Fred;
- Wafula, Erick M;
- Kabami, Jane;
- Owaraganise, Asiphas;
- Mwangwa, Florence;
- Nakato, Hellen;
- Bukusi, Elizabeth A;
- Camlin, Carol S;
- Charlebois, Edwin D;
- Bacon, Melanie C;
- Petersen, Maya L;
- Kamya, Moses R;
- Havlir, Diane V;
- Chamie, Gabriel;
- Team, SEARCH Study
Background
Persons with HIV (PWH) with high mobility face obstacles to HIV care engagement and viral suppression. We sought to understand whether a patient-centered intervention for mobile PWH would improve viral suppression and retention in care, and if so, which subgroups would benefit most.Methods
In a randomized trial, we evaluated the effect of an intervention designed to address barriers to care among mobile (≥2 weeks out of community in previous year) PWH with viral nonsuppression or recent missed visits in Kenya and Uganda (NCT04810650). The intervention included dynamic choice of a "travel pack" (emergency antiretroviral therapy [ART] supply, discrete ART packaging, and travel checklist), multimonth and offsite refills, facilitated transfer to out-of-community clinics, and hotline access to a mobility coordinator. The primary outcome was viral suppression (<400 copies/mL) at 48 weeks. Secondary outcomes included retention in care and ART possession.Results
From April 2021 to July 2022, 201 participants were enrolled and randomized (102 intervention, 99 control): 109 (54%) were female participants and 101 (50%) from Kenya; median age was 37 years (interquartile range: 29-43). At 48 weeks, there was no significant difference in viral suppression in intervention (85%) vs. control (86%). The intervention improved retention in care (risk ratio: 1.06[1.02-1.1]; P < 0.001) and ART possession (risk ratio: 1.07[1.03-1.11]; P < 0.001), with larger effect sizes among persons with baseline nonsuppression and high mobility (≥2 weeks out of community in previous 3 months).Conclusions
Mobile PWH-centered care should be considered for high-risk mobile populations, including nonsuppressed and highly mobile PWH, to improve retention in care and sustain viral suppression over time.Trial registration
NCT04810650.